SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-025721
Filing Date
2023-09-13
Accepted
2023-09-12 20:43:33
Documents
15
Period of Report
2023-09-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vtgn20230912_8k.htm   iXBRL 8-K 22520
2 EXHIBIT 99.1 ex_569125.htm EX-99.1 21955
7 vtgn.jpg GRAPHIC 3002
  Complete submission text file 0001437749-23-025721.txt   187606

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20230912.xsd EX-101.SCH 3410
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20230912_def.xml EX-101.DEF 11425
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20230912_lab.xml EX-101.LAB 15311
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20230912_pre.xml EX-101.PRE 11585
9 EXTRACTED XBRL INSTANCE DOCUMENT vtgn20230912_8k_htm.xml XML 2563
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
Vistagen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 231251424
SIC: 2834 Pharmaceutical Preparations